Lifecore Biomedical, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul Josephs
- Full Time Employees
- 382
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 3515 Lyman Boulevard Chaska MN United States of America 55318
- IPO Date
- Feb 15, 1996
- CIK
- 0001005286
- Website
- lifecore.com
- Similar Companies
- Business
- Lifecore Biomedical, Inc. (LFCR) operates as an integrated contract development and manufacturing organization (CDMO) focused on the development, aseptic filling, and packaging of sterile injectable pharmaceuticals and medical devices. The company manufactures pharmaceutical-grade, non-animal-sourced sodium hyaluronate in bulk form as an active pharmaceutical ingredient and excipient; produces formulated and filled syringes, cartridges, and vials for injectable products treating ophthalmic, orthopedic, and other medical conditions; and provides comprehensive development services including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot and stability studies, process validation, and clinical trial material production for both hyaluronan-based and non-hyaluronan aseptically filled products. These offerings support customers from preclinical through commercial stages, with expertise in highly viscous formulations exceeding 100,000 cP, small molecules, biologics, and combination products, primarily serving pharmaceutical, biotechnology, and medical device companies in the United States. Founded in 1965 and headquartered in Chaska, Minnesota, Lifecore Biomedical maintains U.S.-based manufacturing facilities with proven quality management systems compliant for APIs, excipients, medical devices, drug products, and biologics, including on-site analytical testing, ICH stability studies, serialization, and sterilization options. In recent developments, the company changed its name from Landec Corporation in November 2022 to reflect its focused biomedical operations. In October 2025, Lifecore signed a commercial site transfer agreement with a major multinational pharmaceutical organization to become the exclusive supplier for a leading injectable product following regulatory approval, marking the second deal with this partner in recent months and expanding into new modalities while increasing capacity utilization. Additionally, it secured a preclinical formulation development agreement with an early-stage biotechnology firm and, over fiscal 2025, signed nine new programs including three early-stage ones in the fourth quarter, broadening its commercial and pipeline customer base across ophthalmic therapeutics and beyond. The company plans ERP implementation go-live in Q1 2026 and a shift to calendar-year fiscal reporting, supported by a late-stage pipeline targeting multiple launches from 2026 through 2029.
Company News
Lifecore Biomedical to Participate at Upcoming Industry Conferences
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG
Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lifecore Biomedical, Inc. (LFCR)
Lifecore agrees to acquisition with CVRs up to $160 million
LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Biomedical to Participate at CPHI Global Conference
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026